Prognostic value of upar forms in colon and breast cancer

Project Information

TIMO PIIRONEN

Grant agreement ID: QLK4-CT-1999-51464

Project closed

Start date 1 August 2000

End date 31 July 2002

Funded under

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Total cost € 143 952,00

EU contribution € 143 952,00

Coordinated by

COPENHAGEN UNIVERSITY HOSPITAL
Denmark

Objective

Investigation of the clinical prognostic value of soluble urokinase plasminogen activator receptor (uPAR) forms in blood and tissue extracts from patients with colon and breast cancer, aiming to develop new methods which will aid in the decision-making needed in the management of cancer patients.

Fields of science

• medical and health sciences › clinical medicine › oncology › breast cancer

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-4. - Key action Environment and Health

Call for proposal

Data not available

Funding Scheme

RGI - Research grants (individual fellowships)

Coordinator

COPENHAGEN UNIVERSITY HOSPITAL

• EU contribution: No data
• Address: Stransboulevarden 49 ; 2100 KOEPENHAGEN ; Denmark
• Total cost: No data